Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald N Jones

Showing results (41-50 of 662) with videos related to

Pageof 67
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2013
Treatment of methicillin-susceptible Staphylococcus aureus osteoarticular and prosthetic joint infections: using the oxacillin minimum inhibitory concentration to guide appropriate ceftriaxone useHien M Nguyen, Ronald N Jones
Journal of Drugs in Dermatology : JDD|November 23, 2005
Importance of understanding pharmacokinetic/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureusThomas R Fritsche, Ronald N Jones
International Journal of Antimicrobial Agents|May 15, 2002
Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000Michael A Pfaller, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|August 2, 2002
Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacinDouglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|July 18, 2003
Antagonism between penicillin and erythromycin against Streptococcus pneumoniae: does it exist?Lalitagauri M Deshpande, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|May 6, 2003
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001)Ronald N Jones, Douglas J Biedenbach
Diagnostic Microbiology and Infectious Disease|May 14, 2003
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance programDouglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|September 5, 2006
Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005)Paul R Rhomberg, Ronald N Jones
Archives of Pathology & Laboratory Medicine|June 3, 2006
Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003)Michael A Pfaller, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|September 15, 2009
Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008)Helio S Sader, Ronald N Jones
Pageof 67

Showing results (41-50 of 662) with videos related to

Sort By:
Pageof 67
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2013
Treatment of methicillin-susceptible Staphylococcus aureus osteoarticular and prosthetic joint infections: using the oxacillin minimum inhibitory concentration to guide appropriate ceftriaxone useHien M Nguyen, Ronald N Jones
Journal of Drugs in Dermatology : JDD|November 23, 2005
Importance of understanding pharmacokinetic/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureusThomas R Fritsche, Ronald N Jones
International Journal of Antimicrobial Agents|May 15, 2002
Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000Michael A Pfaller, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|August 2, 2002
Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacinDouglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|July 18, 2003
Antagonism between penicillin and erythromycin against Streptococcus pneumoniae: does it exist?Lalitagauri M Deshpande, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|May 6, 2003
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001)Ronald N Jones, Douglas J Biedenbach
Diagnostic Microbiology and Infectious Disease|May 14, 2003
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance programDouglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|September 5, 2006
Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005)Paul R Rhomberg, Ronald N Jones
Archives of Pathology & Laboratory Medicine|June 3, 2006
Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003)Michael A Pfaller, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|September 15, 2009
Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008)Helio S Sader, Ronald N Jones
Pageof 67